TWF2 and breast cancer: Elevated YAP level accumulation and nuclear accumulation have been reported in hepatocellular carcinoma,[53, 54] lung cancer,[55, 56] breast cancer,[57] skin cancer,[58] and colorectal cancer.[59, 60, 61] In RCC, TWF2 was shown to competitively bind YAP, displacing LATS1, thereby inhibiting YAP phosphorylation and subsequent proteasomal degradation.